{"eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":52,"description":"All participants enrolled in the study - includes participants who were not evaluable for the primary study outcome","id":"EG000","otherNumAffected":4,"otherNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"title":"All Enrolled Participants"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52,"numEvents":4}],"term":"Neutropenia, Grade 4"}],"timeFrame":"Adverse event data were collected between the date of registration and the day 1 of the cycle 6 of FOLFOX chemotherapy (14-day planned cycle length)."}